EPR Biotech News

LC Sciences Pairs Deep Sequencing with Customized Microarrays to Offer New Seq-Array Service for Discovery & Profiling Applications

LC Sciences today announced the launch of its new Seq-Array(SM) services designed to take full advantage of both the latest deep sequencing capabilities and the proven genomics tool – microarray. This combination of technologies advances microRNA research to the next level of depth and understanding that was not possible before ...

LC Sciences First miRNA Microarray Service Provider to Offer Plant MicroRNA Database (PMRD) Probe Content

Taking full advantage of its flexible µParaflo® Biochip Technology, Houston based LC Sciences today announced immediate availability of probe content from the newly created Plant MicroRNA Database (PMRD) for their microRNA (miRNA) microarray customers . This announcement comes immediately following a publication in Nucleic Acids Researchintroducing the public database 1 . ...

Enabling microRNA Discoveries - LC Sciences Tops 100th Customer Publication

LC Sciences announced today the publication of the 100th peer-reviewed study by one of its customers using the company’s microarray service for analyzing microRNA (miRNA) expression profiles and for discovery of novel small RNAs. These studies, by leading researchers in the field, contribute to a fast growing body of knowledge defining ...

LC Sciences announced the availability of probe content miRBase 10.0 for their microRNA (miRNA) microarray customers

Taking advantage of its flexible µParaflo™ Chip Technology, Houston based LC Sciences today announced immediate availability of probe content miRBase 10.0 for their microRNA (miRNA) microarray customers. This announcement comes less than a week after Sanger Institute’s update of their sequence database for known miRNAs (miRBase) 1 to version 10.0 (http://microrna.sanger.ac.uk/sequences). As the jump in version numbers from ...

Advinus, SignalChem Start The Multi-Year, Multi-Target Collaboration On New Anti-Cancer Drugs

Advinus Therapeutics, a research-based pharmaceutical development company promoted by the TATA Group, and SignalChem Pharmaceuticals, a British Columbia-based drug discovery company, have started working on 15 programs based on SignalChem’s proprietary Kinase platform for targeted therapies in oncology. Each program is being developed with corresponding diagnostics and tracers for patient ...

CYTOO Raises 10 M$ (7M€) in Series C Round

CYTOO SA, a company that specializes in cell-based assays, is pleased to announce the closing of a series C funding round of USD 10M (EUR 7M). New investors, Sham and Entrepreneurs Fund (EF), led the round. Existing investors AURIGA Partners and Jacques Lewiner, co-founder and president of the supervisory board ...

Search

The archives run deep. Feel free to search older content using topic keywords.